Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
UBS
Accenture
Merck
Harvard Business School
Novartis
Teva
McKesson
Cerilliant

Generated: October 22, 2017

DrugPatentWatch Database Preview

IBRANCE Drug Profile

« Back to Dashboard

Which patents cover Ibrance, and what generic Ibrance alternatives are available?

Ibrance is a drug marketed by Pfizer Inc and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-eight patent family members in forty-seven countries and five supplementary protection certificates in five countries.

The generic ingredient in IBRANCE is palbociclib. Two suppliers are listed for this compound. Additional details are available on the palbociclib profile page.

Summary for Tradename: IBRANCE

US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list62
Clinical Trials: see list44
Patent Applications: see list61
Drug Prices:see details
DailyMed Link:IBRANCE at DailyMed

Pharmacology for Tradename: IBRANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-001Feb 3, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-002Feb 3, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-001Feb 3, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-003Feb 3, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-002Feb 3, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-003Feb 3, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-001Feb 3, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-001Feb 3, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-002Feb 3, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-001Feb 3, 2015RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: IBRANCE

Country Document Number Estimated Expiration
Hong Kong1104296► Subscribe
Honduras2003000039► Subscribe
MexicoPA04005939► Subscribe
Uruguay27617► Subscribe
Slovenia1470124► Subscribe
Denmark1470124► Subscribe
African Intellectual Property Organization (OAPI)12755► Subscribe
China102295643► Subscribe
Iceland2423► Subscribe
Canada2473026► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: IBRANCE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00010Denmark► SubscribePRODUCT NAME: PALBOCICLIB, EVENTUELT I FORM AF EN FARMACEUTISK ACCEPTABEL ESTER ELLER ET FARMACEUTISK ACCEPTABELT SALT, AMID ELLER PRODRUG; REG. NO/DATE: EU/1/16/1147/001-006 20161111
2017000014Germany► SubscribePRODUCT NAME: PALBOCICLIB, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, ESTERS, AMIDES ODER EINES PRODRUGS HIERVON; REGISTRATION NO/DATE: EU/1/16/1147 20161109
2017013Lithuania► SubscribePRODUCT NAME: PALBOCIKLIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, ESTERIO, AMIDO ARBA PROVAISTO PAVIDALU; REGISTRATION NO/DATE: EU/1/16/1147 20161109
0863Netherlands► SubscribePRODUCT NAME: PALBOCICLIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/16/1147 20161111
0170012 00212Estonia► SubscribePRODUCT NAME: PALBOTSIKLIIB;REG NO/DATE: EU/1/16/1147 11.11.2016
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Express Scripts
Novartis
Queensland Health
Chubb
Farmers Insurance
Harvard Business School
Baxter
Healthtrust
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot